Metaglip Related Published Studies
Well-designed clinical trials related to Metaglip (Glipizide / Metformin)
Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. [2005.05]
Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. [2003.03]
Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. [2002.12]
One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. [1994.07]
Well-designed clinical trials possibly related to Metaglip (Glipizide / Metformin)
Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. [2005.05]
Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. [2003.05]
Improved glucose control decreases the interaction of plasma low-density lipoproteins with arterial proteoglycans. [2002.10]
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. [2001.11]
Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. [2001.08]
Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes? [1999.11]
United Kingdom prospective diabetes study (UKPDS): what now or so what? [1999.01]
Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue. [1997.12]
Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. [1995.03]
Insulin and sulphonylurea in the therapy of type 2 diabetes. [1990.03]
Other research related to Metaglip (Glipizide / Metformin)
Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. [2000.09]
A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose. [1999.08]
Other possibly related research studies
Rational pharmacotherapy in the diabetic hypertension: analysis-prescribing patterns in a general hospital in Taiwan. [2004.12]
Retrobulbar injection of methylprednisolone in diffuse diabetic macular edema. [2004.12]
The role of sulphonylureas in the management of type 2 diabetes mellitus. [2004]
Metformin-associated respiratory alkalosis. [2004.05]
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. [2004]
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. [2003.10]
Presentation and 5-year follow-up of type 2 diabetes mellitus in African-American and Caribbean-Hispanic adolescents. [2003]
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. [2003]
Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. [2003.06]
[Effects of octreotide on serum and urine electrolytes in a patient with parathyroid carcinoma: clinical case] [2001.07]
Current understanding of feline diabetes: part 2, treatment. [2000.03]
Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. [2001]
Differences in pharmacotherapy and in glucose control of type 2 diabetes patients in two neighbouring towns: a longitudinal population-based study. [2001.08]
Serum insulin assay: an important therapeutic tool in management of freshly diagnosed type 2 diabetes mellitus. [2000.08]
Leptin concentrations are related to glycaemic control, but do not change with short-term oral antidiabetic therapy in female patients with type 2 diabetes mellitus. [2000.10]
The effect of oral hypoglycaemic agents on dyslipidaemia in Nigerian patients with newly diagnosed non-insulin dependent diabetes mellitus--a prospective study. [2000.04]
Oral pharmacologic management of type 2 diabetes. [1999.12]
Safety of itraconazole in diabetic patients. [1999]
Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes. [1999.06]
Triple oral antidiabetic therapy. [1998.11]
A retrospective analysis of the efficacy and safety of metformin in the African-American patient. [1997.11]
Oral antidiabetic drugs: an overview. [1996.09]
Changes in prescribing patterns of oral hypoglycaemics in elderly patients, over a period of 10 years: matching with general practitioners' perceptions of their own prescribing. [1996.08]
Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. [1996.08]
Metformin: an antihyperglycemic agent for treatment of type II diabetes. [1996.02]
Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. [1994.10]
Effect of bed time intermediate acting insulin in NIDDM subjects refractory to a combination of sulphonylureas and biguanides. [1992.10]
[Hypoglycemia induced by oral hypoglycemic agents. Records of the French Regional Pharmacovigilance Centers 1985-1990] [1992]
Grinspan's syndrome: a drug-induced phenomenon? [1990.08]
Effects of improved glycaemic control on calcium and magnesium homeostasis in type II diabetes. [1988.09]
|